2. Cell Cycle/DNA Damage Immunology/Inflammation
  3. Checkpoint Kinase (Chk) IFNAR
  4. Monalizumab

Monalizumab  (Synonyms: IPH2201)

Cat. No.: HY-P99032 Purity: 99.69%
COA

Molarity Calculator

Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

For research use only. We do not sell to patients.

Monalizumab Chemical Structure

Monalizumab Chemical Structure

CAS No. : 1228763-95-8

Size Price Stock Quantity
1 mg USD 530 In-stock
5 mg USD 1450 In-stock
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Monalizumab Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Monalizumab

View All Checkpoint Kinase (Chk) Isoform Specific Products:

View All Isoforms
Chk1 Chk2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC)[1][2].

In Vitro

Monalizumab blocks NKG2A and enhances CLL NK-cell mediated cytotoxicity against HLA-E-expressing K562 cells[3].
Monalizumab enhances the Enzalutamide (HY-70002) (10 μM)-induced NK cell activation and killing of prostate cancer cells (LNCaP and 22Rv1)[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Monalizumab Related Antibodies
In Vivo

Monalizumab (50  μg, intratumoral injections, together with 8 millions of activated NK cells) effectively inhibits tumor growth in xenografted HLA-E+ tumors in immunodeficient mice[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: immunodeficient mice xenografted with Cal-27 HLA-E high tumor cell[4]
Dosage: 50 μg, together with 8 millions of activated NK cells
Administration: intratumoral injections
Result: Shows a synergestic antitumor effect.
Enhanced NK-cell killing, and induces lysis of tumor cells.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Monalizumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation

Purity: 99.69%

COA (291 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Monalizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Monalizumab1228763-95-8IPH2201IPH 2201IPH-2201Checkpoint Kinase (Chk)IFNARInterferon-α/β receptorInterferon-alpha/beta receptorCancer immunotherapyCD8 T cellsNK cellsNKG2AInhibitory immune receptorHLA-E/Qa-1head and neck squamous cell carcinomacancer immunotherapyimmune checkpoint inhibitorsrecurrent or metastaticInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Monalizumab
Cat. No.:
HY-P99032
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.